FDA Proposes One Approval for Many Mutations in Personalized Gene Editing
On October 27, 2026, the FDA released a draft guidance that could change how personalized gene-editing treatments reach patients. It is titled "Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management." It describes how one biologics license application (BLA) could cover a gene-editing therapy and many patient-specific versions of it.
The central idea: after a therapy is approved, a developer could add a version for a new patient's mutation using laboratory data instead of a new clinical trial, as long as the new version stays within limits the FDA agreed to in advance.
The problem: too many mutations, too few patients
Many genetic diseases can be caused by hundreds of different mutations in the same gene. A gene editor usually needs a different guide RNA for each one. The guide RNA is the short RNA sequence that steers the editor to the right spot in the genome.
Under the current approach, each of those versions would be handled as its own product. But many mutations are carried by only a handful of people, sometimes by just one. A separate clinical trial for each is impossible. Andrew Byrnes, director of the FDA's Division of Gene Therapy 1, called the per-variant approach "infeasible" and said the new guidance addresses a "critical gap."
The case that showed it can be done
In 2025, doctors at Children's Hospital of Philadelphia and Penn Medicine built a personalized base editor within months for KJ Muldoon, an infant with severe CPS1 deficiency, a rare disorder of the liver's urea cycle. We covered that first personalized base-editing treatment when it was reported.
KJ's case showed that a bespoke editor can be designed, made and given quickly. What was missing was a regulatory path for turning one-off treatments into approved products that other patients, each with a different mutation, could also receive.
How the "Individualized Feature Space" works
One BLA, many variants. A sponsor can submit several product variants in a single BLA. The products must treat a disease caused by known disease-causing variants in a single gene, and all must achieve the same editing outcome. The guidance covers editors that cut DNA and editors that do not.
Limits set in advance. The BLA includes an Individualized Feature Space (IFS). It "defines the allowable limits of variation for the GE components across all product variants," said Jacob Bitterman, lead biologist in the FDA's Division of Gene Therapy 1.
An example. If the only part that changes between versions is the guide RNA's spacer sequence, the IFS would spell out which spacers are allowed. For instance: any spacer that targets a defined class of disease-causing variants in a specified gene and produces the same edit.
Adding variants later. After approval, a new variant that falls inside the IFS is treated as a manufacturing change, not a new product, if clinical and/or in vitro data predict that it will be safe and active enough.
This fits how many editing therapies are built. The editing enzyme and the lipid nanoparticle that carries it into cells can stay the same, while the guide RNA changes from patient to patient. New to guide RNAs and delivery vehicles? The Life-Changing Power of Gene Therapy explains the basics for beginners.
What developers still have to show
The FDA encourages sponsors to design the IFS during clinical development, so their trials produce data that support its boundaries. Sponsors must give a "robust scientific rationale" for where those boundaries sit.
The guidance also covers how to test each variant's safety and potency in the lab, how to validate the manufacturing process, and how to handle labeling, indication statements and drug naming. Safety testing includes looking for unintended genetic changes elsewhere in the genome.
It joins two earlier FDA moves this year: the February "plausible mechanism" pathway for ultra-rare diseases, and a June draft guidance that lets gene-editing developers reuse prior knowledge.
Medicaid access expands too
On the same day, the Centers for Medicare & Medicaid Services (CMS) said it will expand its Cell and Gene Therapy Access Model beyond sickle cell disease. Under the model, CMS negotiates outcomes-based agreements with manufacturers on behalf of state Medicaid programs.
The model launched in 2025 with the sickle cell gene therapies Casgevy and Lyfgenia. Thirty-three states, Washington, D.C., and Puerto Rico signed on, covering about 84% of Medicaid beneficiaries with sickle cell disease. CMS plans to release a request for applications in the coming months. It aims to start negotiations sooner after FDA approval and will also accept therapies that are already on the market.
"A medical breakthrough only matters to patients if they can get it," said CMS Administrator Dr. Mehmet Oz.
How the field reacted
Gene-editing stocks rose on the news: Prime Medicine shares gained about 15% and Beam Therapeutics about 8%, according to BioPharma Dive. Beam CEO John Evans said the approach is "completely supported by the science of base editing."
"For patients with rare genetic diseases, a one size fits all approach to treatment simply does not work," said Acting FDA Commissioner Kyle Diamantas.
What to watch
This is a draft and is not in effect yet. The FDA is taking public comments until November 27, 2026, under docket FDA-2026-D-11783 at regulations.gov.
Key questions include how wide the FDA will let an IFS be, how much lab data will be enough to add each new variant, and how product labels will describe which mutations are covered.
The bottom line
The FDA has proposed a way for one approval to cover a personalized gene editor and its future patient-specific versions. New mutations could be added with lab data instead of new trials. If the final guidance keeps that approach, treatments like KJ Muldoon's could become approved products for many patients with ultra-rare mutations, not just one-off rescues.
Keep exploring with Gene Tech Times
Free guide: subscribe to the Gene Tech Times Briefing on our homepage and get Every FDA-Approved Gene Therapy at a Glance in your inbox.
Watch: 30-second gene therapy Shorts on Gene Tech Times Academy.
Read: The Cheat Codes of Our Genes, real stories of mutations that make some people immune to disease.
New to gene therapy? Start with The Life-Changing Power of Gene Therapy.
As an Amazon Associate, Gene Tech Times earns from qualifying purchases.
— T.N., Gene Tech Times
Comments